The use of sliding scale insulin therapy is widespread but considered suboptimal as the desire to minimise blood sampling,7 combined with the extremely variable response to insulin,1 puts these babies at risk from hypoglycaemia.8 Babies are therefore often managed with a reduction in parenteral nutrition, and potentially inadequate nutritional support, when parenteral nutrition does not contribute as we might want to believe to hyperglycaemia and at a critical time of growth and development.9 10. This evidence concerns the gene INS and Hyperglycemia.